Abstract
In a placebo-controlled trial, we examined the efficacy of a 6-month ("extended") transdermal nicotine therapy vs. the 8-week ("standard") therapy in 471 Caucasian smokers with either normal or reduced rates of nicotine metabolism as determined at pretreatment. Extended therapy was superior to standard therapy in genotypic or phenotypic reduced metabolizers (RMs) of nicotine but not in normal metabolizers (NMs). RMs of nicotine are candidates for extended transdermal nicotine therapy, whereas an alternative therapeutic approach may be needed for those with normal rates of nicotine metabolism.
Publication types
-
Comparative Study
-
Controlled Clinical Trial
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Cutaneous
-
Adult
-
Aryl Hydrocarbon Hydroxylases / genetics
-
Aryl Hydrocarbon Hydroxylases / metabolism
-
Cohort Studies
-
Cytochrome P-450 CYP2A6
-
Delayed-Action Preparations / administration & dosage
-
Delayed-Action Preparations / metabolism
-
Drug Administration Schedule
-
Female
-
Follow-Up Studies
-
Genetic Variation / genetics*
-
Humans
-
Longitudinal Studies
-
Male
-
Middle Aged
-
Nicotine / administration & dosage*
-
Nicotine / metabolism*
-
Nicotine / therapeutic use
-
Predictive Value of Tests
-
Smoking / drug therapy
-
Smoking / genetics*
-
Smoking / metabolism*
-
Smoking Cessation / methods*
-
Treatment Outcome
Substances
-
Delayed-Action Preparations
-
Nicotine
-
Aryl Hydrocarbon Hydroxylases
-
Cytochrome P-450 CYP2A6